{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:37:09Z","timestamp":1791995829168,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clml.2021.05.012","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T08:59:47Z","timestamp":1621846787000},"page":"686-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study"],"prefix":"10.1016","volume":"21","author":[{"given":"Sarah","family":"Lawless","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Sbianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curly","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Lenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.O.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Gonz\u00e1lez Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.05.012_bib0001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.05.012_bib0002","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3324\/haematol.2010.022848","article-title":"Efficacy and outcome of autologous transplantation in rare myelomas","volume":"95","author":"Morris","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.012_bib0003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41409-019-0676-0","article-title":"Results from a multicentre, non-interventional registry study for multiple myeloma patients who received stem cell mobilisation regimens with and without plerixafor","volume":"55","author":"Morris","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.012_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bmt.2014.322","article-title":"Successful mobilization of PBSCs predicts favourable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation","volume":"50","author":"Brioli","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.012_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21556","article-title":"Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"Moreb","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.clml.2021.05.012_bib0006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdq393","article-title":"Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients","volume":"22","author":"Kim","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.05.012_bib0007","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3346\/jkms.2008.23.5.819","article-title":"Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single centre experience","volume":"23","author":"Chong","year":"2008","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clml.2021.05.012_bib0008","first-page":"14","article-title":"Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma","volume":"37","author":"Jin","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2021.05.012_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000446599","article-title":"Immunoglobulin D multiple myeloma: disease profile, therapeutic response, and survival","volume":"136","author":"Wang","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00277-018-3582-4","article-title":"Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era","volume":"98","author":"Chen","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0011","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-020-01060-w","article-title":"Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)","volume":"35","author":"Liu","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.012_bib0012","first-page":"e4011","article-title":"Presentation patterns, diagnostic markers, management strategies, and outcomes of IgD multiple myeloma: a systematic review of literature","volume":"11","author":"Selene","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.clml.2021.05.012_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000486664","article-title":"Efficacy and survival outcome associated with the use of novel agents and autologous stem cell transplantation in cases of immunoglobulin D multiple myeloma in Korea","volume":"139","author":"Kang","year":"2018","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0014","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3816\/CLML.2010.n.078","article-title":"Outcomes of patients with IgD and IgM multiple myeloma undergoing autologous haemopoietic stem cell transplantation: a retrospective CIBMTR study","volume":"10","author":"Reece","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.012_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.12255","article-title":"Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents","volume":"92","author":"Zagouri","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0016","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.21740","article-title":"The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes","volume":"85","author":"Sharma","year":"2010","journal-title":"Am J Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1705881","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD myeloma","volume":"41","author":"Maisner","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.012_bib0018","first-page":"72","article-title":"IgM myeloma or Waldenstrom's macroglobulinemia is the big question?","volume":"9","author":"Bhatt","year":"2014","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.clml.2021.05.012_bib0019","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/10428190600604450","article-title":"IgM multiple myeloma: report of four cases and review of the literature","volume":"47","author":"Annibali","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.05.012_bib0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2007.06969.x","article-title":"IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)","volume":"140","author":"Feyler","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0021","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ajh.24753","article-title":"IgM myeloma: a multicentre retrospective study of 134 patients","volume":"92","author":"Castillo","year":"2017","journal-title":"Am J Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.humpath.2018.09.008","article-title":"IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases","volume":"84","author":"Angelova","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2021.05.012_bib0023","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1703818","article-title":"Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients","volume":"31","author":"Terpos","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.012_bib0024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clml.2015.11.005","article-title":"Outcome of patients with nonsecretory multiple myeloma after autologous hematopoietic stem cell transplantation","volume":"16","author":"Jacobs","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.012_bib0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00277-020-03984-w","article-title":"Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma","volume":"99","author":"Migkou","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clml.2019.09.624","article-title":"Cytogenetic features and clinical outcomes of patients with non-secretory multiple myeloma in the era of novel agent induction therapy","volume":"20","author":"Bharat","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.012_bib0027","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ejh.13351","article-title":"Outcome and characteristics of non-measurable myeloma: a cohort study with population-based data from the Swedish Myeloma Registry","volume":"104","author":"W\u00e5linder","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.05.012_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","volume":"95","author":"Chawla","year":"2015","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:20Z","timestamp":1761871040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2152265021001993"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}